MDMA-Assisted Couple Psychotherapy for PTSD in First Responders: A Phase I Feasibility Study (PACT-MDMA) (PACT-MDMA)

November 11, 2026 updated by: Jeremie Richard

Evaluating the Safety, Feasibility and Preliminary Efficacy of Process-Centred MDMA-Assisted Couple Psychotherapy (PACT-MDMA) for Post-Traumatic Stress Disorder in First Responders

This study is the first step of a research programme on a new treatment for first responders with post-traumatic stress disorder (PTSD): couple therapy in which both partners take MDMA, under medical supervision, in three of fourteen sessions. The treatment is called Process-Centred MDMA-Assisted Couple Psychotherapy, or PACT-MDMA.

Current treatments help many people with PTSD, but many drop out or improve only in part, and few treatments work directly on the relationship, which PTSD strains and which can help recovery. MDMA-assisted therapy has been tested in large trials in the United States, but these studies' designs have been criticised, and the therapy component of the treatment has rarely been specified or measured. No Canadian study has tested MDMA-assisted therapy in first responders, and none has tested it with couples.

This feasibility study at the University of Ottawa will enrol six to ten couples in which one partner is a current or former first responder with PTSD. It asks whether the treatment can be delivered safely, whether couples can be recruited and kept in the study, and whether the sessions and measures work as planned. It does not aim to prove that the treatment works. Two exploratory hypotheses will be examined: that the partner with PTSD will show a reduction in clinician-rated PTSD severity from baseline to the end of treatment that is maintained six months later, and that the other partner will accommodate PTSD symptoms less while both partners report a better relationship over the same period.

A nurse is present and a physician on call during every MDMA session; all sessions are recorded so that the therapy can be checked for fidelity to its written principles; and the research, therapy and medical roles are kept separate. If this phase succeeds, a second phase would compare PACT-MDMA with standard PTSD therapy in about 24 couples in Ottawa and Montreal, and a third would extend the study to several Canadian sites.

Study Overview

Detailed Description

Design. Single-site, single-arm, open-label, mixed-methods Phase I feasibility study with repeated measures at baseline (T0), after each of three treatment cycles (T1 to T3) and at 1, 3 and 6 months after the closing session (T4 to T6). Six to ten couples (12 to 20 participants) will be enrolled. The couple is the unit of treatment; both partners receive the full intervention, including MDMA.

Rationale for the design. Randomisation, placebo and blinding are not used: blinding is not practically possible, since therapists and participants recognise the subjective effects of MDMA, and a placebo or sham-therapy control was judged neither practical nor ethically appropriate for an intensive relational and pharmacological intervention at the feasibility stage. Outcomes are read against published results of cognitive-behavioural conjoint therapy, individual trauma-focused therapies and MDMA-assisted therapy trials. The design responds to the concerns raised in the U.S. FDA review of MDMA-assisted therapy (2024): functional unblinding and expectancy are assumed present and measured (treatment credibility and expectancy at baseline, acute subjective drug effects at each MDMA session); research, therapy and medical functions are assigned to three teams with no overlap in personnel; prior MDMA or psychedelic use is an exclusion criterion; therapists deliver a common protocol under supervision and fidelity is rated from recordings; outcomes are assessed by independent assessors; a 6-month follow-up assesses medium-term durability.

Screening and enrolment. Recruitment is through online advertising, professional networks and printed material in clinics specialising in PTSD near the site. Screening has three stages: a coordinator call (study overview, preliminary eligibility); medical screening by the study physician or delegate (medical and psychiatric history, cardiovascular risk, medications and substances); and a psychotherapeutic intake assessment of both partners (individual stability, relational safety, motivation, capacity for conjoint participation). Participants taking contraindicated medications complete a supervised taper under their own physician before eligibility is confirmed. Final medical eligibility rests with the Medical Director. Each couple receives a CAD 50 gift card on completing the post-treatment questionnaires and CAD 100 on completing the 6-month follow-up.

Intervention. PACT-MDMA is a continuous course of conjoint psychotherapy in which three MDMA-assisted cycles are embedded. Both partners attend all 14 sessions: an introductory session; three cycles each comprising a preparatory session, a full-day MDMA session (6 to 8 hours) and two integration sessions; and a closing session. MDMA sessions are about four weeks apart. Each couple is treated by the same two co-therapists throughout. Sessions are in person, except the introductory and closing sessions, which may be held by telehealth. The psychotherapy is trauma-focused, conjoint and process-centred: participant-led, with safety taking precedence over outcome, consent ongoing and revocable, and preparation and integration treated as essential components rather than adjuncts to dosing. All sessions, including MDMA sessions, are audio- and video-recorded as a condition of participation, for supervision, fidelity rating and safety review.

Investigational product and medical oversight. Laneo™ 2.0 MDMA (MDMA hydrochloride, 50 mg oral capsules; PharmAla Biotech) as a dose of 150 mg, three 50 mg capsules, the same for all participants, with one optional supplemental dose of 50 mg (one capsule) 90 minutes after the initial dose, conditional on medical clearance, the Therapy Team's agreement and the agreement of both partners, given to both partners or to neither (maximum 200 mg per session) ; three dosing sessions per participant (maximum cumulative dose 600 mg MDMA HCl). On each MDMA day a Medical Team member conducts a same-day assessment of each partner and the Medical Director authorises dosing. Vital signs are taken before dosing and before discharge; the co-therapy team observes continuously; on-site nursing staff and an on-call study physician are immediately available; an emergency kit is on site. Predefined stopping rules operate at session, participant and study level, including suspension of enrolment and dosing pending review and notification of the REB and Health Canada. Adverse events are classified by the Medical Team for severity, seriousness, expectedness and relatedness and reported to the REB and Health Canada within the Division 5 timelines.

Analysis. Feasibility is summarised as the numbers screened, eligible, enrolled and retained at each assessment point, with reasons for exclusion and withdrawal; protocol adherence as the proportion of scheduled sessions completed and the frequency and nature of protocol variations, deviations and stopping-rule events; safety as the frequency, severity, seriousness and relatedness of adverse events, reported separately for index participants and partners. Quantitative outcome data are analysed with descriptive statistics and within-subject pre-post comparisons; analyses are exploratory and hypothesis-generating. Qualitative interview data are analysed thematically. The study is not powered to detect statistically significant effects and no formal power calculation applies.

Data management. Data are collected in REDCap and held in encrypted, access-controlled University of Ottawa storage. Participants are identified by a couple code and partner suffix; a single cross-reference file linking identities to codes is held by the project coordinator, separately from research data. Research, medical, therapy, drug-accountability and recording records are held in separate stores with role-based access. Essential records are retained for 15 years as required for Division 5 clinical trials. Results are reported in aggregate with small-sample disclosure safeguards.

Governance and regulation. The sponsor is Dr Jeremie Richard, sponsor-investigator, of the School of Psychology, University of Ottawa; the study is conducted at the School of Psychology's Laboratory for Psychedelic Clinical Research. It requires a Clinical Trial Application and No Objection Letter from Health Canada (Food and Drug Regulations, Division 5), an exemption under section 56(1) of the Controlled Drugs and Substances Act, research ethics board approval and institutional sign-off before enrolment. This feasibility study is the first phase of a planned three-phase programme (feasibility, pilot randomised trial, multi-site trial).

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ontario
      • Ottawa, Ontario, Canada, K1N 6N5
        • University of Ottawa, School of Psychology, Laboratory for Psychedelic Clinical Research
        • Principal Investigator:
          • Simon Hatcher, MD
        • Sub-Investigator:
          • Jérémie Richard, PhD
        • Sub-Investigator:
          • Jean-François Jodouin, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria (both partners unless stated):

  • Aged 18 years or older
  • One partner (the index participant) is a current or former first responder with a diagnosis of post-traumatic stress disorder or complex post-traumatic stress disorder
  • In a relationship of at least 12 months and currently cohabiting
  • Fluent in French or English (reading, writing and speaking)
  • Willing to attend the therapy in person at the study site and to have all sessions audio- and video-recorded
  • Able to name a supportive person not participating in the study as emergency contact
  • Willing and able to provide informed consent and to take part in all study procedures
  • The study is inclusive of all gender identities, sexual orientations, cultural backgrounds and religious affiliations

Exclusion Criteria (both partners, since both receive MDMA):

  • Current diagnosis of a substance use disorder (moderate to severe)
  • Current use of contraindicated psychoactive medications (e.g., SSRIs, MAOIs), herbal supplements, or prescription or non-prescription medications that cannot be safely tapered before the study
  • Current or previous use of MDMA or other psychedelics
  • Uncontrolled hypertension, significant cardiovascular disease, or another medical condition contraindicating MDMA
  • Pregnancy or breastfeeding
  • Current participation in another clinical trial
  • History of psychotic disorder or of a disorder with psychotic features, bipolar I disorder, or borderline personality disorder
  • Active suicidal ideation, recent suicide attempt, or danger to others
  • Cognitive impairment that limits the ability to provide informed consent or to take part in therapy
  • Current conventional or PTSD-focused psychotherapy, or another procedure likely to affect study outcomes (e.g., other psychedelic-assisted therapy, electroconvulsive therapy, transcranial magnetic stimulation)
  • Relational ambivalence, including current plans to separate or divorce
  • High-conflict relationship including physical violence

Final medical eligibility rests with the Medical Director, who may exclude on clinical judgement even where formal criteria are met.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PACT-MDMA

Couples in which one partner is a current or former first responder with PTSD. Both partners receive Process-Centred MDMA-Assisted Couple Psychotherapy: 14 conjoint sessions delivered by the same two co-therapists, comprising an introductory session, three treatment cycles (preparatory session, full-day MDMA session, two integration sessions) about four weeks apart, and a closing session. In each MDMA session both partners receive an oral dose of 150 mg MDMA hydrochloride, with one optional 50 mg supplemental dose 90 minutes later, given to both partners or to neither.

Laneo 2.0 MDMA (75% R(-)-MDMA / 25% S(+)-MDMA hydrochloride; PharmAla Biotech Inc.), 50 mg hard oral capsules; a non-racemic composition used clinically in Australia. Oral dose of 150 mg MDMA HCl (three 50 mg capsules) per MDMA session, the same for all participants regardless of body weight or sex, with one optional 50 mg supplemental (booster) dose (one capsule) 90 minutes after the initial dose, conditional on same-day medical clearance, the Therapy Team's agreement and both partners' agreement, and given to both partners or to neither (maximum 200 mg per session). Capsules are ingested intact under the direction and supervision of an authorised Medical Team member. Three MDMA sessions per participant, about four weeks apart (maximum cumulative dose 600 mg MDMA HCl). Both partners of each couple are dosed concurrently.

Other Names:
  • LaNeo MDMA

Conjoint, trauma-focused, process-centred psychotherapy delivered to both partners by a co-therapy team of two therapists who remain constant across all sessions. Fourteen sessions: an introductory session (60 min); three cycles, each with a preparatory session (90 min), an MDMA session (6 to 8 h) and two integration sessions (90 min each, the first within 24 to 48 h of dosing, the second within two weeks); and a closing session (60 min). Introductory and closing sessions may be held by telehealth; all other sessions are in person. Sessions are not organised around a fixed sequence of exercises; content follows what emerges, under written principles rated for fidelity from session recordings.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recruitment: number of couples screened, eligible and enrolled, and enrolment rate
Time Frame: From the opening of recruitment through the end of enrolment (approximately 183 days after recruitment opens)

Numbers of couples screened, found eligible and enrolled, with reasons for exclusion; couples enrolled per month of open recruitment.

From the opening of recruitment through the end of enrolment (approximately 183 days after recruitment opens)
Retention: proportion of enrolled couples completing the three treatment cycles and each assessment point
Time Frame: From enrolment to the 6-month follow-up (T6 = day 304), with completion assessed on days 42, 70, 122, 152, 213 and 304

Proportion of enrolled couples who complete all three treatment cycles (closing session, T3) and who complete the assessments at T1 to T6, with reasons for withdrawal.

From enrolment to the 6-month follow-up (T6 = day 304), with completion assessed on days 42, 70, 122, 152, 213 and 304
Protocol adherence: proportion of scheduled sessions completed per protocol, and protocol variations, deviations and stopping-rule events
Time Frame: From the introductory session (day 14) to the closing session (T3 = day 122)

Proportion of the 14 scheduled sessions completed per protocol for each couple; frequency and nature of protocol variations, deviations and applications of the session-, participant- and study-level stopping rules.

From the introductory session (day 14) to the closing session (T3 = day 122)
Therapist fidelity to the PACT-MDMA model (PACT-MDMA Fidelity Rating Scale, PACT-FRS)
Time Frame: From the introductory session (day 14) to the closing session (T3 = day 122)

Adherence, competence and differentiation ratings by independent raters from recordings of all MDMA sessions and a stratified sample of other sessions; therapist self-ratings; inter-rater reliability; drift events across a therapist's consecutive ratings.

From the introductory session (day 14) to the closing session (T3 = day 122)
Safety: frequency, severity, seriousness and relatedness of adverse events
Time Frame: From enrolment (T0 = day 0) to the 6-month follow-up (T6 = day 304)

Adverse events, serious adverse events, serious adverse reactions and suspected unexpected serious adverse reactions, classified by the Medical Team by severity, seriousness, expectedness and relatedness and including psychological and relational events, reported separately for index participants and partners.

From enrolment (T0 = day 0) to the 6-month follow-up (T6 = day 304)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in clinician-rated PTSD symptom severity (CAPS-5), index participant
Time Frame: Baseline (T0 = day 0), post-treatment (T3 = day 122), and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Clinician-Administered PTSD Scale for DSM-5, structured interview assessing DSM-5 PTSD diagnosis and symptom severity across the 20 DSM-5 symptoms, administered by an independent assessor to the partner with PTSD.

Baseline (T0 = day 0), post-treatment (T3 = day 122), and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in self-reported PTSD symptom severity (PCL-5), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

PTSD Checklist for DSM-5, 20-item self-report mapping onto the DSM-5 PTSD symptoms. Completed separately by each partner.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in partner accommodation of PTSD symptoms (SORTS), support partner
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Significant Others' Responses to Trauma Scale, assessing partner responses and accommodation of PTSD symptoms; completed by the partner without PTSD.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in relationship satisfaction (Couple Satisfaction Index, CSI), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Couple Satisfaction Index, self-report measure of relationship satisfaction.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in relationship quality (Quality of Relationships Inventory, QRI), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Quality of Relationships Inventory: Support, Depth and Conflict subscales.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in attachment anxiety and avoidance (ECR-M16), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Modified Experiences in Close Relationships scale, 16 items.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in depressive symptoms (PHQ-9), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Patient Health Questionnaire-9, 9-item measure of depressive symptom severity.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in anxiety symptoms (GAD-7), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Generalized Anxiety Disorder-7, 7-item measure of generalised anxiety symptom severity.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Suicidal ideation and behaviour (C-SSRS), both partners
Time Frame: Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Columbia-Suicide Severity Rating Scale; presence and severity of suicidal ideation and behaviour.

Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in experiential avoidance (BEAQ), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Brief Experiential Avoidance Questionnaire, 15-item self-report measure of experiential avoidance.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in psychological flexibility (MPFI-24), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Multidimensional Psychological Flexibility Inventory, 24-item short form covering the six flexibility and six inflexibility processes of the Hexaflex model; higher-order flexibility and inflexibility scales.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in posttraumatic growth (PTGI), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Posttraumatic Growth Inventory, 21 items, five domains of perceived positive change after trauma.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in perceived social support (MOS-SSS), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Medical Outcomes Study Social Support Survey, 19-item measure of perceived functional social support.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Cross-cutting psychiatric symptoms (DSM-5-TR Level 1 Cross-Cutting Symptom Measure, Adult), both partners
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

23-item self-report screen of transdiagnostic symptom domains.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Alcohol, cannabis and drug use (AUDIT, CUDIT-R, DUDIT), both partners
Time Frame: Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Brief self-report screens for hazardous alcohol, cannabis and drug use.

Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Working alliance (WAI-SR), both partners
Time Frame: After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122)

Working Alliance Inventory, Short Revised, client-rated Bond, Tasks and Goals.

After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122)
Treatment credibility and expectancy (CEQ), both partners
Time Frame: Baseline (T0 = day 0)

Credibility/Expectancy Questionnaire.

Baseline (T0 = day 0)
Trait absorption (Tellegen Absorption Scale), both partners
Time Frame: Baseline (T0 = day 0)

34-item true-false trait measure.

Baseline (T0 = day 0)
Acute subjective drug effects (DEQ), both partners
Time Frame: At each of the three MDMA sessions, respectively on days 28, 56 and 84

Drug Effects Questionnaire visual-analogue ratings (feel, like, high, want more).

At each of the three MDMA sessions, respectively on days 28, 56 and 84
Session phenomenology (PIQ, EBI, 5D-ASC, MEQ-30), both partners
Time Frame: At each of the three MDMA sessions, respectively on days 28, 56 and 84

Psychological Insight Questionnaire; Emotional Breakthrough Inventory (6 items); 5-Dimensional Altered States of Consciousness Rating Scale; Mystical Experience Questionnaire-30 (exploratory for MDMA).

At each of the three MDMA sessions, respectively on days 28, 56 and 84
General psychotherapeutic change mechanisms (GCMQ), both partners
Time Frame: After each treatment cycle (T1, T2, T3), respectively on days 42, 70 and 122

General Change Mechanisms Questionnaire, 25 items, five mechanisms.

After each treatment cycle (T1, T2, T3), respectively on days 42, 70 and 122
Persisting effects (PEQ-SF), both partners
Time Frame: After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304); not at baseline

Persistent Effects Questionnaire Short Form, 14 items plus 3 on spirituality, well-being and meaning.

After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304); not at baseline
Participant experience (semi-structured qualitative interview), each partner separately
Time Frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Thematic analysis of interviews following the PACT-MDMA Participant Experience Interview Guide: experience of self, of the relationship, of the MDMA sessions, of the periods between sessions; barriers and facilitators.

Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Jérémie Richard, PhD, University of Ottawa
  • Study Director: Jean-François Jodouin, PhD, University of Ottawa
  • Study Director: Simon Hatcher, MD, University of Ottawa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2027

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2028

Study Registration Dates

First Submitted

November 5, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared. The study enrols 12 to 20 participants in couples, so that individual-level data carry a risk of re-identification even after de-identification; results will be reported in aggregate with small-sample disclosure safeguards, as set out in the study's data protocol.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe